St. Savvas’ Hospital General Anti-Cancer and Oncological Hospital of Athens
- Address
- Alexandras 171 Avenue, 11522 Athens, Greece
St. Savvas' Hospital General Anti-Cancer and Oncological Hospital of Athens
St. Savvas' Hospital General Anti-Cancer and Oncological Hospital of Athens is a specialized oncology institution dedicated to advancing cancer treatment through participation in cutting-edge clinical research. The center focuses on evaluating novel therapeutic approaches across multiple cancer types, with particular emphasis on thoracic malignancies and head and neck cancers.
- Non-small cell lung cancer immunotherapy combinations with PD-L1 targeted agents
- Head and neck squamous cell carcinoma treatment following chemoradiation therapy
- Small cell lung cancer relapsed disease management with antibody-drug conjugates
The hospital's research portfolio demonstrates expertise in evaluating checkpoint inhibitor therapies such as dostarlimab and pembrolizumab, as well as innovative antibody-drug conjugates targeting B7-H3. Through participation in Phase 3 clinical trials, St. Savvas' Hospital contributes to establishing new standards of care for patients with locally advanced unresected tumors and relapsed disease, offering access to promising investigational treatments that may improve outcomes for cancer patients in Athens and beyond.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in St. Savvas’ Hospital General Anti-Cancer and Oncological Hospital of Athens
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of the oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP inhibitor (PARPi) niraparib in adult participants with solid tumors. | Glaxosmithkline Research & Development Limited | Phase I/II | Not Recruiting | — | Dec 2025 |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dostarlimab | 2 | Unknown | 2024-05-29 | 2024-10-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.